Company: MIRA
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001183
Chunk: 684

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 6
Chunk 684
---
 capital 
    $32,500  
    $426,345 

See
notes to consolidated financial statements

F-7

MIRA
PHARMACEUTICALS, INC.

SUPPLEMENTAL
CASH FLOW INFORMATION

Non-cash
financing and investing activities:

The
Company recorded deferred offering costs of $32,500 during the year ended December 31, 2024 in association with the At the Market Agreement
and charged these costs to additional paid in capital.

The
Company recorded the fair value of a total of 1,000,000 shares of common stock issued to Bay Shore Trust during the year ended December
31, 2023 which totaled approximately $3.5 million to deferred finance costs. The Company had amortized approximately $0.7 million of
deferred offering costs as non-cash amortization of debt issuances costs in accordance with Generally Accepted Accounting Principles
(“GAAP”). As of December 31, 2023, this agreement was paid in full. This resulted in a write-off of unamortized deferred
financing costs, in the amount of $2.8 million which was recorded as interest expense.

The
Company recorded the fair value of a total of 157,170 shares of common stock issued to Bay Shore Trust during the year ended December
31, 2023 totaling approximately $1.1 million to record Bay Shore Trust conversions of a line of credit and interest to shares of common
stock.

The
Company recorded the fair value of a total of 35,715 shares of common stock issued to the MZ Group during the year ended December 31,
2023 totaling $0.25 million in lieu of fees for investor relation services.

On
November 15, 2023, the Company entered a warrant agreement and recorded the fair value of a total of 700,000 shares of common stock issued
to MIRALOGX, LLC which totaled $1,832,600 to expense.

See
notes to consolidated financial statements

F-8

MIRA
PHARMACEUTICALS, INC.

NOTES
TO THE FINANCIAL STATEMENTS

DECEMBER
31, 2024 AND 2023

Note
1. Description of business and summary of significant accounting policies:

Overview

MIRA
Pharmaceuticals, Inc. (NASDAQ: MIRA) is a clinical-stage pharmaceutical development company advancing two neuroscience programs targeting
neurologic and neuropsychiatric